Share Price:

APNASPENAspen Pharmacare Hldgs2193888 (0.40%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen 3rd in FM 2006 Top Companies

Aspen was ranked third in the June 2006 Financial Mail Top Companies survey. Companies are ranked based on consistent performance for five years. Aspen wasn’t on the radar screen a few years ago; now it’s in third position and has a market capitalization in excess of R14 billion. Aspen’s share delivered a highly credible 112%… Continue reading Aspen 3rd in FM 2006 Top Companies

Dr. Judy Dlamini appointed chairman designate at Aspen

Dr Judy Dlamini will succeed Archie Aaron as chairman of the board of directors of Aspen Pharmacare Holdings Limited (“Aspen”) after Aspen’s annual general meeting of shareholders which is scheduled to take place in November 2007. Archie Aaron has decided to step down as chairman having served in this position since 1999. He will remain… Continue reading Dr. Judy Dlamini appointed chairman designate at Aspen

Aspen to manufacture influenza medicine oseltamivir

Aspen (APN), South Africa’s largest listed pharmaceutical company, today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche’s continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic… Continue reading Aspen to manufacture influenza medicine oseltamivir

Aspen signs MOU for TB products

Johannesburg – JSE listed Aspen (APN) and Indian based Lupin Limited have entered into a Memorandum of Understanding for the establishment of a 50:50 joint venture for the development, manufacture and global marketing of selected anti-tuberculosis (TB) products. The JV will also investigate opportunities to enter the Malaria market. Stephen Saad, Aspen Group Chief Executive… Continue reading Aspen signs MOU for TB products

Aspen records 45% increase in HEPS

Aspen records 45% increase in HEPS Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded impressive interim results for the period ended December 2005. Headline earnings per share (HEPS) increased 45 percent to 86.3 cents (59.4 cents). Revenue increased by 27 percent to R1,687 billion (R1.4 billion). Operating profit rose 34 percent… Continue reading Aspen records 45% increase in HEPS

Aspen and BMS conclude strategic ARV deal

JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer and the largest generic manufacturer in the southern hemisphere, has signed a non-exclusive license and technology transfer collaboration agreement with New York based Bristol-Myers Squibb (BMS) for the manufacture and distribution of a generic version of Atazanavir, a new generation anti-retroviral (ARV). BMS selected Aspen… Continue reading Aspen and BMS conclude strategic ARV deal

Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs

Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30-50 Percent for 50 Countries Clinton Also Confirms that Nearly a Quarter-Million People Living with HIV are Benefiting from First-Line HIV/AIDS Drug Agreements his… Continue reading Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.